With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4677-20-7,4-(2-Bromoethyl)tetrahydropyran,as a common compound, the synthetic route is as follows.
Example 44A Di-tert-butyl [2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl](2-oxo-2-{6-[2-(tetrahydro-2H-pyran-4-yl)ethoxy]-1-benzofur-2-yl}ethyl)malonate To a mixture of 200 mg (0.36 mmol) of the compound from Example 43A in 0.75 ml of DMF under argon were added, at RT, 45 mg (0.40 mmol) of potassium tert-butoxide and, after stirring for 5 min at RT, 86 mg (0.44 mmol) of 4-(2-bromoethyl)tetrahydro-2H-pyran, dissolved in 0.25 ml of DMF. The mixture was stirred at a bath temperature of 70 C. for 1.5 h. After cooling to RT, in each case 50 ml of water and ethyl acetate were added, and after phase separation, the aqueous phase was extracted once with 50 ml of ethyl acetate. The combined organic phases were dried over sodium sulphate, filtered and concentrated. The residue was taken up in dichloromethane and purified by column chromatography (silica gel, mobile phase: cyclohexane/ethyl acetate 7:3). 82 mg (32% of theory, purity 94%) of the title compound were obtained. 1H-NMR (400 MHz, CDCl3): delta [ppm]=8.30 (dd, 1H), 8.08 (d, 1H), 7.89 (td, 1H), 7.77-7.72 (m, 1H), 7.57-7.51 (m, 2H), 7.01 (d, 1H), 6.93 (dd, 1H), 4.60-4.53 (m, 2H), 4.07 (t, 2H), 3.98 (dd, 2H), 3.71 (s, 2H), 3.42 (td, 2H), 2.69-2.63 (m, 2H), 1.84-1.76 (m, 3H), 1.73-1.65 (m, 2H), 1.54-1.30 (m, 2H, hidden), 1.49 (s, 18H). LC/MS (Method 1, ESIpos): Rt=1.48 min, m/z=676 [M+H]+.
4677-20-7, As the paragraph descriping shows that 4677-20-7 is playing an increasingly important role.
Reference£º
Patent; BAYER PHARMA AKTIENGESELLSCHAFT; BECK, Hartmut; LI, Volkhart Min-Jian; CANCHO GRANDE, Yolanda; TIMMERMAN, Andreas; BROHM, Dirk; JOeRIssEN, Hannah; BOGNER, Pamela; GERISCH, Michael; LANG, Dieter; (120 pag.)US2017/121315; (2017); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics